Slingshot members are tracking this event:
Fitusiran (ALN-AT3) Phase 1 Open Label Extension study initial data expected in late 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Dec 03, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fitusiran, Aln-at3, Antithrombin, Hemophilia, Rare Bleeding Disorders, Phase 1, Open Label Extension